Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Bayer to partner with Twist Bioscience to accelerate drug discovery
Friday, October 06, 2023Bayer AG has entered into an antibody discovery option and license agreement with Twist Bioscience Corporation a company offering highquality synthetic DNA using its silicon platform
Tenaya Therapeutics Doses First Patient in the MyPeak-1™ Phase 1b Clinical Trial of TN-201 for the Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy
Friday, October 06, 2023Tenaya Therapeutics Inc NASDAQ TNYA a clinicalstage biotechnology company with a mission to discover develop and deliver potentially curative therapies that address the underlying causes of heart disease today announced that the first patient has bee...
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Thursday, October 05, 2023Kineta Inc Nasdaq KA a clinicalstage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today an update on its ongoing Phase clinical trial evaluating KVA in patients...
Kineta Announces Positive KVA12123 Monotherapy Safety and Biomarker Data from its Ongoing Phase 1/2 VISTA-101 Clinical Trial
Wednesday, October 04, 2023Kineta Inc Nasdaq KA a clinicalstage biotechnology company focused on the development of novel immunotherapies in oncology that address cancer immune resistance announced today an update on its ongoing Phase clinical trial evaluating KVA in patients...
Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Received U.S. FDA Fast Track Designation for BI 764532 for the Treatment of Extensive Stage Small Cell Lung Cancer and Extrapulmonary Neuroendocrine Cancers
Wednesday, October 04, 2023Oxford BioTherapeutics OBT a clinical stage oncology company with a pipeline of immunooncology and Antibody Drug Conjugate ADCbased therapies today announces that the US Food and Drug Administration FDA has granted Fast Track designation to BI...
FluoGuide receives FDA Orphan Drug Designation for FG001 in high-grade glioma REGULATORY
Wednesday, October 04, 2023The FDAs Office of Orphan Products Development grants orphan drug designation to FG to support the development of this diagnostic agent for the management of malignant glioma as a rare disorder affecting fewer than people in the US Orphan Drug desig...
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine for the Treatment of Acute Myeloid Leukemia
Tuesday, October 03, 2023Moleculin Biotech Inc Nasdaq MBRX Moleculin or the Company a clinical stage pharmaceutical company with a growing pipeline including Phase clinical programs
ANI Pharmaceuticals Announces FDA Approval and Commercial Availability of New 1-mL Vial Size of Purified Cortrophin® Gel
Tuesday, October 03, 2023ANI Pharmaceuticals Inc ANI or the Company Nasdaq ANIP today announced US Food and Drug Administration FDA approval and commercial availability of a mL vial USP units mL of Purified Cortrophin Gel repository corticotropin injection USP Cortrophin Ge...
Cassava Sciences Completes Patient Enrollment for Pivotal Phase 3 Clinical Trial of Oral Simufilam in Alzheimer’s Disease
Monday, October 02, 2023Cassava Sciences Inc Nasdaq SAVA a biotechnology company today announced the completion of patient enrollment in a pivotal Phase clinical trial Eight hundred four Alzheimers patients are enrolled in this month trial
Calliditas Presents Data from the NefIgArd Phase 3 trial at the 17th International Symposium on IgA Nephropathy (IIgANN) Tokyo 2023
Saturday, September 30, 2023Calliditas Therapeutics AB NASDAQ CALT NASDAQ Stockholm CALTX Calliditas today announced the presentations of new biomarker and subgroup analyses from the Phase NefIgArd study with Nefecon TARPEYO budesonide delayed release capsulesKinpeygo in adult...
